Positive IDMC recommendation based on an interim analysis of the masitinib phase 3 study in first-line treatment of castrate-resistant prostate cancer
19/06/2018 – AB Science expects study to be completed in 2019.
19/06/2018 – AB Science expects study to be completed in 2019.